The patents cover claims related to the chemical structures, sequences of the peptide constituents and method of manufacture of OHR/AVR118.
Ohr Pharmaceutical CEO Irach Taraporewala said the patents strengthen the company’s OHR/AVR118 cancer cachexia program currently being investigated in a Phase II clinical trial.
"OHR/AVR118 has the potential to greatly benefit advanced cancer patients suffering from the debilitating effects of cachexia," Taraporewala added.
"Stronger, more stable patients have a much better chance of tolerating the intense chemotherapies and radiation therapies involved in treating late stages of cancer."
Ohr is a pharmaceutical company focused on the clinical development of new drugs for underserved therapeutic needs in growing markets.